NCT05806801Recruiting
Metabolic Adaptations to Weight Loss With and Without Exercise
Source: ClinicalTrials.gov · Last updated 14 Apr 2026
Brief summary (registry, in English)
Study Purpose: The combination of caloric restriction and exercise is the most common first-line treatment for obesity-related disorders, yet we know very little about how these two very different treatments work together. A deeper understanding about mechanisms underlying the health benefits of adding exercise to a weight loss program will not only aid efforts to optimize more effective lifestyle interventions, but it can also uncover novel targets for the treatment/prevention of obesity-related diseases. Although a reduction in body fat is the fundamental adaptation to weight loss, we know almost nothing about the effects that adding exercise has on structural and functional changes within fat tissue that may further enhance metabolic health. This is very important because many obesity-related metabolic health complications are tightly linked with abnormalities in abdominal fat tissue. We argue exercise-induced modifications in abdominal fat tissue will reveal persistent health benefits even if some weight is regained Study Summary: 10% Weight Loss Phase - Subject participation in the study will involve a series of metabolic tests before, at midpoint, and after undergoing a 10% weight loss program (with or without exercise training depending on group randomization). During this, subjects will be randomized into one of two different experimental groups: 1. Moderate Intensity Continuous Training (MICT) exercise group 2. No exercise (control) group Follow-up Phase: After completing the metabolic testing post-weight loss, all study-related diet and exercise supervision will end and subjects will be free to make their own choices regarding diet and exercise/physical activity behavior. Subjects will then be asked to complete follow-up testing at 2-, 4- and 6- months post-weight loss. Total involvement in the study for each subject will likely be about 10-13 months (4-7 months during weight loss phase, 6 months during follow-up phase).
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 68 (estimated)
- First submitted
- 28 Mar 2023
- Start date
- 19 Jul 2023
- Primary completion date
- 1 Aug 2027
- Lead sponsor
- University of Michigan
- Diseases
- Obesity
- NCT number
- NCT05806801
What you commit to
- Study type: Interventional
- Planned participants: 68
- From 19 Jul 2023 to the primary completion date, 1 Aug 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Evidence/history of cardiovascular disease, diabetes or other metabolic disease
- Allergies/hypersensitivity to local anesthetics of the amide type (e.g., lidocaine)
- Anti-coagulant medication (e.g., Coumadin, Rivaroxaban) and Lidocaine allergy/sensitivity are exclusion criteria for the biopsy procedure.
Lab values
- Medications known to affect lipid or glucose metabolism
- Prior experience of hypersensitivity to insulin, human albumin, and potassium chloride injection.
- History of hyperkalemia or potential for developing hyperkalemia (including but not limited to taking drugs that may induce hyperkalemia such as cardiac glycosides or potassium sparing diuretics)
Other
- EKG abnormalities
- Pregnant or lactating
- Tobacco or e-cigarette use
Who the study is looking for
- Age: 18-40
- Body Mass Index: 30-40 kg/m2
- Weight stable (±3kg for greater than or equal to about 2 months)
- No regularly planned exercise/physical activity
- Women must have regularly occurring menses and must be premenopausal
Age in the registry: 18 years to 40 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Michigan Coordinator of this site? Confirm its status | Ann Arbor | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.